Rubicon Research Acquires US Manufacturing Facility in New Jersey

<h1>Rubicon Research Acquires US Manufacturing Facility in New Jersey</h1>

Rubicon Research Limited, a leading integrated pharmaceutical company, has announced the acquisition of a manufacturing facility in East Brunswick, New Jersey, USA, significantly expanding its global footprint. The asset was acquired by AdvaGen Holdings, Rubicon’s wholly owned subsidiary, from InvaTech Pharma Solutions, LLC for an enterprise value of USD 2.9 million.

The transaction was completed on July 21, 2026. As part of the deal, Rubicon has taken over the facility, which includes the lease, all associated equipment, records, and permits. This acquisition provides the company with a US manufacturing presence comparable in size to its existing facility located in Satara, though it does not encompass any product approvals or filings.

AdvaGen Holdings emerged as the successful bidder after participating in a court-supervised competitive bid process conducted under Section 363 of the U.S. Bankruptcy Code and has since entered into a long-term lease agreement for the site.

The operational facility is equipped to manufacture oral solid and oral liquid formulations. It holds a history of being USFDA inspected for over a decade, having undergone three successful inspections. A recent unannounced inspection by the USFDA in May 2026 resulted in a Form 483 issuance containing six observations, which were noted as largely procedural and unrelated to data integrity. Rubicon reported that Invatech responded to the Form 483 within the stipulated time, completing corrective actions expected by the USFDA, thus paving the way for a successful conclusion of the inspection.

The acquired site is strategically positioned to focus on Rubicon’s specialty and high-value products, as well as fulfilling demand from various US government departments. The company plans to commence manufacturing at the New Jersey site in calendar year 2027, pending the completion of its quality management system implementation.

Commenting on the strategic move, Parag Sancheti, CEO of Rubicon, stated that the ability to manufacture within the United States strongly complements the growing portfolio of branded and specialty products. He emphasized the value of being closer to customers and the enhanced resilience this facility brings to the global supply chain. Additionally, he noted that the site shares a wall with AimRx, a subsidiary, which operates the US distribution center, offering a unique opportunity for efficient expansion. Rubicon plans to make significant capital investments over the next three years to expand both the breadth and depth of manufacturing capabilities at the facility.

Rubicon Research Limited was established in 1999 and is described as an R&D led, vertically integrated pharmaceutical company specializing in the development, manufacturing, and commercialization of differentiated pharmaceutical products. The company currently maintains a portfolio exceeding 80 pharmaceutical products across multiple therapeutic areas, including CNS. Rubicon operates globally inspected facilities that are regulated by authorities such as the U.S. Food and Drug Administration (USFDA), UK MHRA, and Australian TGA. The company maintains a robust R&D organization of over 200 scientists located in its development centers in Mumbai and Toronto.

RUBICON Stock Price Movement​

Rubicon Research Limited shares slipped by 2.96% to settle at ₹1466.4 today, having shed ₹44.90 from the previous close. The stock saw a traded volume of 386,080 shares during the session.